会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 98. 发明申请
    • METHOD OF SCREENING DRUG-RESISTANCE PROTEIN OF MYCOBACTERIUM TUBERCULOSIS
    • US20080187922A1
    • 2008-08-07
    • US11871932
    • 2007-10-12
    • Honghai WangLu ZhangQingzhong WangJun YueMin ZhangYing XuBingdong ZhuJiuling WangYaqing Qie
    • Honghai WangLu ZhangQingzhong WangJun YueMin ZhangYing XuBingdong ZhuJiuling WangYaqing Qie
    • C12Q1/68
    • C12Q1/689C12Q1/18C12Q2600/156G01N33/5695G01N2333/35G01N2500/00
    • The present invention belongs to the field of molecular biology. Specially, the invention relates to the screenings of a new drug target, a vaccine antigen and a test target of anti-tuberculosis treatment. Specially, based on the differential proteome technology and by the techniques of gene sequencing, in vitro protein expression, immunological detection and gene recombination, the invention primarily certifies that the up-regulated expression of Protein Rv2629 and the mutation of Gene 191A/C of Mycobacterium tuberculosis are related to the Rifampicin (RFP) drug-resistance, which provides useful information for the drug-resistance detection of Mycobacterium tuberculosis, the novel drug design and the vaccine development. Firstly, the drug-resistant strains are cultured and the proteins from drug resistance strains and sensitive strains are isolated respectively. Secondly, the proteins from the drug resistance strains and the sensitive strains are compared to determine the differential protein sites, such that the drug-resistant proteins are identified by means of Mass Spectrometry. Next, the up-regulated expression of Protein Rv2629 and the mutation of gene are correlated to the drug-resistance of Mycobacterium tuberculosis by means of gene sequencing technique. Finally, after the gene cloning, the in vitro expression and purification of the protein, the wild-type and mutant-type recombinant protein of Rv2629 are obtained. The polyclonal antibody is prepared, and the protein subcellular localization is carried out. The Minimum Inhibitory Concentrations (MICs) of the strains containing different plasmids obtained by the transformation of recombinant shuttle plasmids are also measured. The gene encoding the protein Rv2629 in the genome of Mycobacterium tuberculosis is isolated and is up-regulation expressed in a Rifampicin (RFP)-resistant strains. And the A/C gene mutation at nucleotide 191 which is related to drug-resistance is detected. The relationship between the mutation and the Rifampicin (RFP)-resistance is primarily certified by molecular biology technique and the in vitro experiments. This invention provides methods used to accurately isolate and identify the drug-resistance protein of Mycobacterium tuberculosis. The A/C mutation of Rv2629 at nucleotide 191 related to the drug-resistance of Mycobacterium tuberculosis is isolated, which shows new approach for the further study of Mycobacterium tuberculosis drug-resistant mechanism, the rapid detection of clinical drug-resistance strains, as well as the developments of new drug targets and vaccines.
    • 100. 发明申请
    • Additives and modified tetrabasic sulfate crystal positive plates for lead acid batteries
    • 铅酸电池的添加剂和改性四硫酸盐结晶阳极板
    • US20060110524A1
    • 2006-05-25
    • US10992987
    • 2004-11-19
    • Lu ZhangDouglas DavenportJason Connell
    • Lu ZhangDouglas DavenportJason Connell
    • B05D5/12
    • H01M4/56H01M4/21H01M4/72
    • A positive electrode plate-making process for a lead acid battery that produces an active material precursor comprising tetrabasic lead sulfate crystals with an average crystal width less than 20 μm. The process includes mixing a lead and/or lead oxide powder and a paste additive with sulfuric acid to form a positive electrode paste composition, wherein the paste additive comprises ground tetrabasic lead sulfate crystals having an average particle size in the range of 1-20 μm. The paste is then cured on a positive battery grid to form a positive electrode plate having the desired active material precursor containing tetrabasic lead sulfate crystals with an average crystal width less than 20 μm. In an embodiment, curing is performed directly after applying the paste to the grid, with no intermediate steaming process.
    • 一种铅酸蓄电池的正极板制造方法,其制造包含平均晶体宽度小于20μm的四价硫酸铅晶体的活性物质前体。 该方法包括将铅和/或氧化铅粉末和糊状添加剂与硫酸混合以形成正极浆料组合物,其中所述糊状添加剂包括平均粒度在1-20μm范围内的研磨的四价硫酸铅晶体 。 然后将该糊剂固化在正电池栅格上以形成具有所需活性物质前体的正极板,该活性物质前体含有平均晶体宽度小于20μm的四价硫酸铅晶体。 在一个实施方案中,在将糊剂施加到网格之后直接进行固化,而不进行中间蒸汽处理。